APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently in phase II.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Risa, 7100, No
- Phone
- +47 73 49 4002
- co****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- apimtherapeutics.com
- HQ
- Risa
Apim Therapeutics Questions
Apim Therapeutics's helpline number is +47 73 49 4002
Apim Therapeutics's website is apimtherapeutics.com
Apim Therapeutics's LinkedIn profile is https://no.linkedin.com/company/apim-therapeutics
Apim Therapeutics has
7 employees.
View email and phone details for 7
employees at Apim Therapeutics.
Apim Therapeutics's industry is
Biotechnology Research
Apim Therapeutics's top competitors are
Bioinvent International Ab,
Aerocells,
Amatsii Limited,
Tob Management,
Oncosyne,
Mcarthur And Associates Gmbh,
Precision Oncology Consulting,
Calluna Pharma,
Ariceum Therapeutics,
Zelluna.
Apim Therapeutics's support email address is contact@apimtherapeutics.com
Apim Therapeutics's categories are Biotechnology Research
Apim Therapeutics's founding year is 2010
